Standout Papers

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis 2019 2026 2021 2023 434
  1. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis (2019)
    Bruce E. Sands, Laurent Peyrin‐Biroulet et al. New England Journal of Medicine

Immediate Impact

1 from Science/Nature 58 standout
Sub-graph 1 of 22

Citing Papers

Programmable Food-Derived Peptide Coassembly Strategies for Boosting Targeted Colitis Therapy by Enhancing Oral Bioavailability and Restoring Gut Microenvironment Homeostasis
2025 Standout
Understanding the therapeutic toolkit for inflammatory bowel disease
2025 Standout
1 intermediate paper

Works of Raquel Rogers being referenced

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
2019 Standout

Author Peers

Author Last Decade Papers Cites
Raquel Rogers 545 433 179 11 680
Jason Harper 302 449 246 18 761
TM Bayless 510 332 252 9 597
S. Lockton 437 345 112 13 722
Bart Lemmens 616 528 249 17 743
Emmanuel René 646 542 277 9 814
P. RUTGEERTS 467 356 249 15 743
Dalia Hacohen 385 257 187 15 792
Lorenzo Oliva 525 456 311 12 758
Patricia K. Heath 534 348 178 11 831
Jean-François Simon 501 407 262 13 648

All Works

Loading papers...

Rankless by CCL
2026